ERBB2 and breast neoplasm: For screening we selected the p53 mutant, triple negative (ERα negative, PR negative and ERBB2 negative) breast tumour cell line HCC1143, based on previous work suggesting that ATRi might have utility in TP53 mutant cancers6, 9, 24, 25.